🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BFF

Found 18 matching trials

A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma

PHASE4

This Phase IV study is an a multi-centre, randomised open label, two way cr...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-11-14

Trial ID

NCT02233803

Treatments Being Tested

NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler NEUMOTEX 400 (Budesonide 400 mcg)Salbutamol 100 mcg pMDI

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

PHASE3

This is a variable length study to evaluate the efficacy and safety of bude...

Status

Completed

Location

Research Site

Start Date

2021-03-01

Trial ID

NCT04609904

Treatments Being Tested

BGF MDI 320/28.8/9.6 μg BGF MDI 320/14.4/9.6 μg BFF MDI 320/9.6 μg BFF pMDI 320/9 μg

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

PHASE3

A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-C...

Status

Completed

Location

Research Site

Start Date

2016-08-09

Trial ID

NCT03262012

Treatments Being Tested

BGF MDI (PT010)GFF MDI (PT003)BFF MDI (PT009)Symbicort® Turbohaler® Inhalation Powder

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

PHASE3

This study will investigate the effect of Budesonide, Glycopyrronium, and F...

Status

Completed

Location

Research Site

Start Date

2023-10-24

Trial ID

NCT06067828

Treatments Being Tested

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Treatment B: Budesonide and Formoterol Fumarate Treatment C : Placebo

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

PHASE3

Study comparing the same drugs as a dual combination product (budesonide an...

Status

Completed

Location

Research Site

Start Date

2019-09-10

Trial ID

NCT04078126

Treatments Being Tested

BFF Symbicort Turbuhaler

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-05-31

Trial ID

NCT02766608

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg FF MDI 9.6 μg BD MDI 320 μg Symbicort® TBH 400/12 μg BID

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-04-29

Trial ID

NCT02727660

Treatments Being Tested

BFF MDI (PT009) 320/9.6 μg BFF MDI (PT009) 160/9.6 μg FF MDI (PT005) 9.6 μg

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

PHASE2

The purpose of this study is to evaluate the effect of 2 different GP meter...

Status

Recruiting

Location

Research Site

Start Date

2026-04-14

Trial ID

NCT07525375

Treatments Being Tested

GP MDI BFF MDI Placebo MDI

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

PHASE3

This is a 24 week study to evaluate the efficacy and safety of budesonide a...

Status

Completed

Location

Research Site

Start Date

2022-01-12

Trial ID

NCT05202262

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg BD MDI 320 μg Open-label Symbicort TBH 320/9 μg

Previous Next